Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Preventice, Inc.
MINNEAPOLIS, Oct. 29, 2013 /PRNewswire/ -- Preventice®, Inc., announced today that Kevin Nickels has joined the company as chief operating officer. Nickels brings nearly 40 years experience in product and business development; general management; and an ability to raise and monetize invested capital -26 of which were spent at medical device companies-to his new role at Preventice. He will be responsible for leading the global market expansion of the BodyGuardian® Remote Monitoring System (BodyGuardian) and for continuing to evolve and enhance operations for the company's remote monitoring solutions.
According to Jon Otterstatter, co-founder, president and CEO of Preventice, Nickels will use his notable experience with start-up medical device companies to help guide Preventice down the path of long-term business growth and to navigate the regulatory complexities that come with commercializing medical devices today.
"Kevin has built an impressive track record of taking early-stage medical technologies and successfully bringing them to market while creating a sustainable infrastructure for ongoing growth," said Otterstatter. "Preventice and its partners have already demonstrated the clinical value of BodyGuardian. I'm confident that Kevin will help us solidify a leadership position in clinical deployments of remote monitoring solutions in the global marketplace."
Prior to joining Preventice, Nickels was president and CEO of CytoPherx, Inc., a biotech company evaluating a cell processing therapy for the treatment of acute kidney injury/severe sepsis. Prior to CytoPherx, Nickels was president and CEO of Rubigo Technologies, Inc., a transdermal drug delivery company targeting the treatment of skin cancer; chairman of Advanced Vein Therapy, Inc., a developer of a catheter-based drug delivery system for vascular surgeons and interventional radiologists; president and CEO of Celleration, Inc., a medical device company serving the advanced wound care and tissue regeneration market that established itself as an emerging standard of care with a unique CPT reimbursement code; and president and CEO of Kinesis Medical, the developer of a therapeutic back brace. Before entering the medical device industry in 1997, Nickels was a business unit leader for Rosemount Aerospace where he led and acquired multiple business units.
"Now, more than ever, the world needs technology that will create greater efficiencies in care delivery and that will improve healthcare outcomes and lower healthcare costs," said Nickels. "Preventice is poised to make a significant impact on cost, quality and outcomes with its remote monitoring solutions, and I'm thrilled to be joining the company at such an exciting time."
About Preventice, Inc.
Preventice, Inc., is a privately owned company and leading developer of mobile health applications and remote monitoring systems that connect mobile, home-based, and on-premise technologies to deliver continuous patient care across the health continuum-wherever an individual patient might be. Applications from Preventice create a constant connection and exchange of data between healthcare providers, life science companies and their patients. Current applications from Preventice address high-cost conditions and health management opportunities, including prescription medication management, cardiac care, sleep apnea, diabetes management, and migraine headaches. Preventice is headquartered in Minneapolis, with offices in Rochester, Minn., and Fargo. N.D. To learn more about Preventice, visit www.preventice.com.
About BodyGuardian Remote Monitoring System
Preventice, Inc., has licensed the remote monitoring algorithms for the BodyGuardian Remote Monitoring System (BodyGuardian) from Mayo Clinic. The BodyGuardian detects, records and wirelessly transmits physiological data to support remote monitoring of non-lethal, cardiac arrhythmias in ambulatory patients. Data is transmitted to the Preventice mHealth platform, where it can be stored for later retrieval.
The BodyGuardian sensor adheres to the patient's skin and is smaller than a cell phone, giving patients complete mobility and freedom to go about their normal lives without restriction. Physicians and medical professionals can securely view the captured medical information anytime, any place on devices such as the iPad®, or online. Physicians can retrieve patient data and reports, or choose to receive alerts based on changes in select biometrics.
For more information:
Barbara Tabor, APR
Tabor Communications Consulting for Preventice
©2012 PR Newswire. All Rights Reserved.